文献速递心脏核医学肿瘤 PET/CT

锝-99m标记抗程序性死亡配体1单域抗体SPECT/CT:一种用于心肌PD-L1表达成像的新型生物标志物

[99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression.
PubMed 文献 · EJNMMI Res · 2023-05-17

本研究在10例肺癌患者中,于基线及抗PD-1治疗9周后行胸部[99mTc]NM-01 SPECT/CT,测量左、右心室与血池比值。左心室心肌PD-L1表达在基线至少为骨骼肌的3倍,右心室至少为2倍,且重复测量信度极高(ICC 0.99)。作者认为该技术可无创定量心肌PD-L1表达,有望用于免疫检查点抑制剂相关心肌炎等研究。

要点

  • 基线左心室心肌与骨骼肌摄取比值为3.71±0.77 vs 0.98±0.20(p<0.001),心肌表达至少为骨骼肌3倍。
  • 基线右心室心肌与骨骼肌摄取比值为2.49±0.63 vs 0.98±0.20(p<0.001),心肌表达至少为骨骼肌2倍。
  • 左心室与血池比值重复测量ICC为0.99(95%CI 0.94-0.99,p<0.001),平均偏倚-0.05±0.14。

核心结论

  • 本研究首次报告可无创定量心脏PD-L1表达而无需侵入性心肌活检,具有高信度和特异性。
  • 作者认为该技术可用于研究免疫检查点抑制剂相关心肌炎和心肌病中的心肌PD-L1表达。

研究设计与样本

  • 本研究为在肺癌患者(n=10)中开展的[99mTc]NM-01 SPECT/CT成像研究。
  • 患者在基线及抗PD-1治疗9周后接受胸部[99mTc]NM-01 SPECT/CT,测量左心室和右心室与血池比值。
  • 左心室最大值与背景骨骼肌最大值进行比较,采用组内相关系数和Bland-Altman分析确定重复测量信度。

主要发现

  • 左心室与血池比值基线为2.76±0.67,9周为2.55±0.77(p=0.42)。
  • 右心室与血池比值基线为1.82±0.32,9周为1.76±0.45(p=0.67)。
  • 基线左心室心肌与骨骼肌比值3.71±0.77 vs 0.98±0.20(p<0.001),心肌表达至少为骨骼肌3倍。
  • 基线右心室心肌与骨骼肌比值2.49±0.63 vs 0.98±0.20(p<0.001),心肌表达至少为骨骼肌2倍。
  • 左心室与血池比值重复测量ICC 0.99(95%CI 0.94-0.99,p<0.001),平均偏倚-0.05±0.14(95%一致性界限-0.32至0.21)。

关键数值与推荐

  • 左心室与血池比值基线2.76±0.67 vs 9周2.55±0.77(p=0.42)。
  • 右心室与血池比值基线1.82±0.32 vs 9周1.76±0.45(p=0.67)。
  • 基线左心室心肌与骨骼肌比值3.71±0.77 vs 0.98±0.20(p<0.001)。
  • 基线右心室心肌与骨骼肌比值2.49±0.63 vs 0.98±0.20(p<0.001)。
  • 左心室与血池比值ICC 0.99(95%CI 0.94-0.99,p<0.001),平均偏倚-0.05±0.14(95%一致性界限-0.32至0.21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Myocardial programmed death-ligand 1 (PD-L1) expression is implicated in immune checkpoint inhibitor (ICI)-associated myocarditis. Measurement of myocardial PD-L1 expression may have potential use as a mechanistic and predictive biomarker. The aim of this study was to determine non-invasive assessment of myocardial PD-L1 expression using [99mTc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT. METHODS: Thoracic [99mTc]NM-01 SPECT/CT was performed in lung cancer patients (n = 10) at baseline and 9-weeks following anti-programmed cell death protein 1 (PD-1) therapy. Baseline and 9-week left ventricular and right ventricular to blood pool ratios (LVmax:BP) and (RVmax:BP) were measured. LVmax was compared to background skeletal muscle (musclemax). Intra-rater reliability was determined by intraclass correlation coefficient (ICC) and Bland-Altman analysis. RESULTS: Mean LVmax:BP values were 2.76 ± 0.67 at baseline vs 2.55 ± 0.77 at 9 weeks (p = 0.42). Mean RVmax:BP was 1.82 ± 0.32 at baseline vs 1.76 ± 0.45 at 9 weeks (p = 0.67). Myocardial PD-L1 expression was at least threefold greater than skeletal muscle at baseline for the LV (LVmax to musclemax 3.71 ± 0.77 vs 0.98 ± 0.20 (p < 0.001)) and at least twofold for the RV (LVmax to musclemax 2.49 ± 0.63 vs 0.98 ± 0.20 (p < 0.001)). There was excellent intra-rater reliability for LVmax:BP with ICC 0.99 (95% confidence interval 0.94-0.99, p < 0.001), mean bias -0.05 ± 0.14 (95% limits of agreement -0.32 to 0.21). There were no major adverse cardiovascular events or myocarditis during follow-up. CONCLUSION: This study is the first to report PD-L1 expression of the heart that can be quantified non-invasively without invasive myocardial biopsy, with high reliability and specificity. This technique can be applied to investigate myocardial PD-L1 expression in ICI-associated myocarditis and cardiomyopathies. Clinical trial registration PD-L1 Expression in Cancer (PECan) study (NCT04436406). https://clinicaltrials.gov/ct2/show/NCT04436406 June 18th, 2020.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Nazir MS, Hughes DJ, Chand G, et al. [99mTc]-labelled anti-Programmed Death-Ligand 1 single-domain antibody SPECT/CT: a novel imaging biomarker for myocardial PD-L1 expression. EJNMMI Res. 2023. PMID: 37195370. doi:10.1186/s13550-023-00990-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。